Belite Bio, Inc to Present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference May 15th

Company Overview - Belite Bio, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for degenerative retinal diseases with significant unmet medical needs, including Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD) [4] - The lead candidate, Tinlarebant, is an oral therapy aimed at reducing toxin accumulation in the eye and is currently undergoing multiple clinical trials, including a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) for STGD1, as well as a Phase 3 study (PHOENIX) for GA [4][7] Recent Developments - Dr. Nathan L. Mata, the Chief Scientific Officer, will present at the dbVIC - Deutsche Bank American Depositary Receipt (ADR) Virtual Investor Conference on May 15, 2025, providing an opportunity for investors to engage with the company [1] - The DRAGON trial, a pivotal global Phase 3 trial for Tinlarebant in adolescent STGD1 subjects, is expected to be completed by Q4 2025, with an independent DSMB recommending submission of interim analysis data for regulatory review [7] - The ongoing PHOENIX trial for Tinlarebant in GA subjects has enrolled over 460 participants [7] Event Details - The virtual investor conference will take place on May 15, 2025, at 12:30 pm ET, allowing real-time interaction between investors and the company [2] - Participation in the conference is free of charge, and an archived webcast will be available for those unable to attend live [3][2]